ClinicalTrials.gg
RecruitingNCT05692999PulseUpdated Jun 25, 2025

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

A Phase 3 interventional study of Pembrolizumab 200 mg Q6W and Pemetrexed 500 mg/m^2 Q3W in Metastatic Non-squamous Lung Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 37 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies testing pembrolizumab in Lung Neoplasms — 10 open to participants now, 22 under way, 9 of them phase 3. pembrolizumab · Lung Neoplasms.

Planned enrollment
2nd of 39
1,166 · median 46
Started
2023
with 3 others
Phase 3
8 of 39
2 open now
Primary completion
2029-01
later than 16 of 21 live
Registered
26th of 39
by date

Among the 39 studies testing pembrolizumab in Lung Neoplasms, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, reaches primary completion later than 16 of the 21 other live ones, and was the 26th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 39 studies testing pembrolizumab in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Lung Neoplasms, or all of them as a file.
02

Study summary

Pulse is a randomized non-inferiority phase III clinical trial assessing a new mode of immunotherapy administration based on increased interval time between 2 infusions as maintenance treatment in Pulse arm compared with the conventional administration in Control arm.

In both treatment arms, pembrolizumab alone or combined with pemetrexed is allowed as maintenance treatment. Indeed :

In Pulse arm : Pembrolizumab 200 mg will be administered to patients every 6 weeks (Q6W) plus, in the absence of contra-indication pemetrexed 500 mg/m\^2 will be administered every 3 weeks (Q3W).

In control arm : Pembrolizumab 200 mg will be administered to patients every 3 weeks (Q3W) or 400 mg every 6 weeks plus,in the absence of contra-indication pemetrexed 500 mg/m\^2 will be administered every 3 weeks (Q3W).

03

Conditions studied

  • Metastatic Non-squamous Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A) To be checked before the induction phase (only for patient included before induction phase) :

  1. or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC).
  2. Non-operable / non-irradiable stage III or stage IV.
  3. Patient must be eligible to receive 3 or 4 cycles of induction treatment combination with pembrolizumab plus platinum (cisplatin or carboplatin) and pemetrexed.
  4. In the presence of an EGFR mutation, an ALK or ROS1 rearrangement the patient must have received at least one specific targeted therapy line.
  5. Age ≥ 18 years old.
  6. Performance status 0 or 1.
  7. Signed .
  8. Patient affiliated to a social security system or beneficiary of the same.

B) To be checked before the maintenance phase (for all patient) :

  1. Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC).
  2. Non-operable / non-irradiable stage III or stage IV.
  3. Received 3 or 4 cycles of induction treatment combination with pembrolizumab plus platinum (cisplatin or carboplatin) and pemetrexed.
  4. Patient must be eligible to receive maintenance pembrolizumab with or without pemetrexed, last induction chemotherapy cycle within 42 days before randomization.
  5. Stable disease, partial or complete response according to 1.1 criteria after induction chemotherapy and pembrolizumab. Targets lesions are not required before randomization.
  6. In the presence of an EGFR mutation, an ALK or ROS1 rearrangement the patient must have received at least one specific targeted therapy line (not needed a second time if already checked before induction phase).
  7. Patients with baseline will be eligible in case of stability or no evidence of progression and if they remain clinically stable.
  8. Age ≥ 18 years old.
  9. Performance status 0 or 1.
  10. Signed informed consent (only for patient included after induction phase).
  11. Patient affiliated to a social security system or beneficiary of the same.
  12. > 30 ml/min by Cockcroft-Gault* or in case that patient will start maintenance just with pembrolizumab but ≥ 45 ml/min if the patient will receive pemetrexed plus pembrolizumab.

    *Cockcroft- Gault Formula:

    • Female CrCl = [(140 - age in years) x weight in kg x 0.85] / 72 x serum creatinine in mg/dL;
    • Male CrCl = [(140 - age in years) x weight in kg x 1.00] /72 x serum creatinine in mg/dL.
  13. Neutrophils ≥ 1500/μL and ≥ 100 000/μL.
  14. ≤ 1.5 upper limit normal ().
  15. Transaminases, Alkaline phosphatase ≤ 2.5 x the ULN except in case of liver (5 x ULN).
  16. Patients might have received platinum-based chemotherapy as an or neoadjuvant treatment, or with radiotherapy for a localized lung cancer, provided that the chemotherapy was ended more than 6 months before the first cycle of induction chemotherapy.
  17. Patients might have received previous as an adjuvant or neoadjuvant treatment, or as a consolidation treatment after radiotherapy for a localized lung cancer, but the immune checkpoint inhibitors must be finished at least than 12 months before the first cycle of induction chemotherapy for advanced stage.
  18. A woman is eligible for the study if she is no longer likely to procreate (physiologically unfit to carry out a pregnancy), which includes women who have had: a hysterectomy, an oophorectomy, a bilateral tubal ligation.

    women:

    • Patients not using hormone replacement therapy should have had a complete cessation of menstruation for at least one year and be over 40 years of age, or, if in doubt, have an FSH (Follicle Stimulating Hormone) level > 40 mIU/mL and an estradiol level \< 40 pg/mL (\< 150 pmol/L).
    • Patients using hormone replacement therapy must have had a complete cessation of menstruation for at least one year and be over 45 years of age or have evidence of menopause (FSH and estradiol levels) before starting hormone replacement therapy.
  19. Women who are likely to procreate are eligible if they have a negative serum pregnancy test in the week before the first dose of treatment and preferably as close as possible to the first dose and if they agree to use an effective method during the course of the study through 4 months after the last dose of study medication.

Sexually active males patients must agree to use condom during the study and for at least 4 months after the last study treatment administration. Also, it is recommended their women of partner use a highly effective method of contraception.

Exclusion criteria

Exclusion Criteria:

A) To be checked before the induction phase (only for patient included before induction phase) :

  1. Mixed small-cell, squamous-cell carcinoma.
  2. Mental or psychological illness that does not allow the patient to give .
  3. Pregnant or breastfeeding women.
  4. History of or chronic or C.
  5. Active or uncontrolled infection.
  6. History of one or more of the following cardiovascular disorders in the previous 6 months:

    • Coronary artery bypass or peripheral arterial bypass, cardiac angioplasty or stent.
    • Myocardial infarction
    • Severe or unstable angina pectoris
    • Peripheral vascular disease, pulmonary embolism or untreated thromboembolic events, stroke or . Note: Patients with recent deep vein thrombosis (including pulmonary embolism) treated with anticoagulant for at least 4 weeks and clinically stable are eligible.
    • Congestive heart failure class III or IV as defined by the
  7. Concomitant treatment with another experimental treatment or participation in another clinical trial.

B) To be checked before the maintenance phase (for all patient) :

  1. Presence of grade 3 or 4 toxicity related to pembrolizumab limiting maintenance treatment continuation.
  2. Mixed small-cell, squamous-cell carcinoma.
  3. at a dose greater than 20 mg per day of prednisone or equivalent.
  4. Patient unable to follow the therapeutic program.
  5. Mental or psychological illness that does not allow the patient to give informed consent.
  6. Pregnant or breastfeeding women.
  7. Ongoing systemic therapy (cyclophosphamide, aziatropin, methotrexate, thalidomide and anti-TNF).
  8. Active diseases. History of autoimmune diseases including myasthenia gravis, lupus erythematosus, rheumatoid arthritis, irritable bowel syndrome, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis. Patients with a history of autoimmune hypothyroidism treated with a stable dose of hormone replacement therapy are eligible. Patients with diabetes treated with insulin are eligible.
  9. History of idiopathic pulmonary fibrosis, organized pneumonia (i.e., obliterating bronchiolitis), drug-induced lung disease or active signs of pneumonia, pulmonary infiltration (regardless of cause) detected on the baseline chest CT-scan.
  10. History of any other hematologic or primary solid tumor unless in remission for at least 2 years and without specific treatment (as example, not allowed hormonal therapy to replace for breast cancer or hormonal therapy substitution in prostate cancer). pT1-2 prostatic cancer Gleason score \< 6, superficial bladder cancer, non-melanoma skin cancer or carcinoma in situ of the cervix are allowed.
  11. Presence of a condition or condition that makes patient participation in the study inappropriate, including serious unresolved or unstable toxicities from previous administration of another experimental treatment or any medical condition that could interfere with patient safety, obtaining consent or compliance with study procedures.
  12. Administration of a within the 4 weeks before day 1 of Cycle 1 or administration of a live attenuated vaccine planned for the duration of the study. The flu vaccine can be given during the flu season (approximately from October to May). Patients should not receive a live attenuated influenza vaccine during the 4 weeks preceding day 1 of Cycle 1 and should not receive this type of vaccine during the study.
  13. History of HIV or chronic hepatitis B or C (not needed a second time if already checked before induction phase).
  14. Active or uncontrolled infection.
  15. History of one or more of the following cardiovascular disorders in the previous 6 months:

    • Coronary artery bypass or peripheral arterial bypass, cardiac angioplasty or stent.
    • Myocardial infarction
    • Severe or unstable angina pectoris
    • Peripheral vascular disease, pulmonary embolism or untreated thromboembolic events, stroke or transient ischemic attack. Note: Patients with recent deep vein thrombosis (including pulmonary embolism) treated with anticoagulant for at least 4 weeks and clinically stable are eligible.
    • Congestive heart failure class III or IV as defined by the NYHA
  16. Concomitant treatment with another experimental treatment or participation in another clinical trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,166 participants (estimated)

Study arms

  • Experimental
    Pulse Arm

    Drug: Pembrolizumab 200 mg Q6W · Drug: Pemetrexed 500 mg/m^2 Q3W

  • Active comparator
    Control Arm

    Drug: Pemetrexed 500 mg/m^2 Q3W · Drug: Pembrolizumab 200 mg Q3W or 400 mg Q6W

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

    defined as the time elapsed between the date of randomization and the date of death whatever the cause. Patients alive at the date of last follow-up will be censored at that date.

    Time frame: 6 years

Secondary outcomes

  1. Progression-free survival

    defined by the time between the randomization date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

    Time frame: 6 years

  2. Duration of response between both treatment arms.

    Duration of response among patients who had a response (CR/PR) after the 4 induction cycles. It is defined by the time between first response observed (i.e. randomization date) and first event observed (progression, secondary malignancy or death in case of no previous progression).

    Time frame: 6 years

  3. Assessment of quality of life between both treatment arms via the EORTC QLQ-C30 questionnaire.

    Patient reported outcomes via the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 was developed to assess the quality of life of cancer subjects and is the most widely used cancer-specific HRQoL instrument. It contains 30 items and measures five functional dimensions (physical, role, emotional, cognitive, and social), three symptom items (fatigue, nausea/vomiting, and pain), six single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact) and global health and quality of life. The global health and quality of life scale uses a 7-point scale scoring with anchors (1=very poor and 7=excellent); the other items are scored on a 4 point scale (1=not at all, 2=a little, 3= quite a bit, 4=very much).

    Time frame: 6 years

  4. Assessment of quality of life between both treatment arms via the EORTC QLQ-LC13 questionnaire.

    Patient reported outcomes via the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13). The EORTC QLQ-LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss. It is scored on a 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much).

    Time frame: 6 years

  5. Assessment of quality of life between both treatment arms via the EQ-5D-5L questionnaire.

    Patient reported outcomes via the 5-level EuroQol-5D (EQ-5D-5L questionnaire). The EQ-5D-5L essentially consists of five health state dimensions include the following: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-point scale from 1 (extreme problem) to 5 (no problem). The EQ-5D-5L also includes a graded (0 = The worst health you can imagine, to 100 = The best health you can imagine) vertical visual analog scale on which the subject rates his or her general state of health at the time of the assessment.

    Time frame: 6 years

  6. Treatment tolerance in both treatment arms

    Frequency of adverse events according to CTCAE V5

    Time frame: 6 years

  7. Economic evaluation

    An important cost reduction per patient associated to treatment de-escalation is expected. We will compare the costs between the two arms. Time horizon extends from randomization to the date of last follow-up. Direct medical costs will be estimated from the French national health insurance perspective (Système National des Données de Santé, SNDS).

    Time frame: 6 years

  8. Population pharmacokinetic analysis in both arms (primary objective)

    The primary objective of the PK study will be to evaluate the systemic exposition (Ctrough) of pembrolizumab in both arms.

    Time frame: 6 years

  9. Population pharmacokinetic analysis in both arms (secondary objective)

    The secondary objective of the PK study will be to use the clearance evolution of the pembrolizumab as marker of the response to explore the potential correlation between clearance evolution and the survival.

    Time frame: 6 years

  10. Evaluate the saturation of PD-1 on circulating lymphocytes in both arms

    Calculate the % of saturation of PD-1 on fresh circulating lymphocytes at baseline and during treatment in both arms.

    Time frame: 6 years

  11. Evaluate the target engagement pharmacodynamics (PD) in both arms

    Target engagement pharmacodynamics (PD) will be assayed using the interleukin-2 (IL-2) stimulation ratio at baseline and during treatment in both arms.

    Time frame: 6 years

07

Study locations

35 of 37 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jan 2029, 70 months after the start.

Of 65 non-industry phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 99. This study's planned 70 months is close to that.

Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 20, 2023
StartActual
Mar 20, 2023
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05692999
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Mar 20, 2023
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 25, 2025

Study contacts

Benjamin BESSE
Contact
Benjamin.BESSE@gustaveroussy.fr
+33(0)1 42 11 62 61
Lynda MATI
Contact
lynda.mati@gustaveroussy.fr
+33(0)1 42 11 37 30
Benjamin BESSE
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion